Quality of Life and Nutritional Improvements in Cirrhotic Patients

Inclusion Criteria: * Male and female gender of Age 18 years or older * Liver cirrhosis defined as one or more of the following: Radio-graphically proven portal hypertension (CT with nodular appearance) or Liver biopsy with cirrhosis * Model for End Stage Liver Disease (MELD) score \< 20 * Willingness to provide written informed consent, and participate in all study requirements * Sodium greater than 130 meq/L * Conn Score \< 2 Exclusion Criteria: * Active alcohol consumption * Serum total bilirubin level \> 5 mg/dl * History of hepatocellular carcinoma (HCC) and malignancies other than basal cell carcinoma of the skin * Pregnant or breastfeeding women * Subject has renal insufficiency requiring routine dialysis * Poorly controlled diabetes as defined by HgA1C \> 10 * Narcotic/psychotropic usage other than a stable dose of antidepressant and/or methadone. Neurontin (gabapentin) and Lyrica (pregabalin) are permitted if the subject has been on a stable dose for at least 2 months prior to the screening visit and no change of dosing is expected throughout the length of the trial * Any of the following diagnoses: * HIV * Evidence of severe concomitant illness or any condition that makes them unsuitable for the study in the opinion of the investigator(s) * Subject has received an investigational drug within 30 days prior to enrollment